Continuous Manufacturing of Biologics, an USP/BioPhorum Joint Workshop
Join us in-person in Maryland for the Continuous Manufacturing of Biologics, an USP/BioPhorum Joint Workshop where Just-Evotec Biologics will be presenting.
Who’s Attending
- Magnus Schroeder, VP Process & Product Design at Just-Evotec Biologics
- Todd Ireland, Senior Director Business Development at Just-Evotec Biologics
Speaking Session | 7 December at 2:05pm
Advancing Integrated, Continuous Manufacturing in a Flexible cGMP Facility (J.POD®)
At Just – Evotec Biologics, we are using an integrated, continuous manufacturing platform to deliver low-cost, high quality biopharmaceutical products as part of our mission to dramatically increase global access to biologics. Our assessment of cost reduction drivers has guided our technology platform towards two key areas: 1) the development of a continuous bioprocessing platform using an intensified, high productivity, longer duration cell culture process, and 2) the design of J.POD®, a flexible and modular cGMP manufacturing facility that leverages single-use technology with a lower cost of capital investment and greater speed of construction. This presentation will discuss the drivers and strategy used by Just – Evotec Biologics to develop an integrated, continuous manufacturing platform which is able to provide both low cost and flexibility for cGMP manufacturing of early/late-clinical phase and commercial biologics. Additionally, the presentation will highlight our first Clinical Ph I through Commercial facility in North America, J.POD® Redmond, Washington (US), which launched production in September 2021, and now manufactures antibodies and other therapeutic proteins. Key quality and regulatory considerations associated with process and facility design concepts for operation of a multi-product facility will be highlighted.
Presented by Magnus Schroeder, VP Process & Product Design at Just-Evotec Biologics
Speaker
-
Magnus SchroederVP Process and Product DesignMagnus Schroeder joined Just-Evotec Biologics in August 2021 as VP Process and Product Design. He is leading the P&PD team at the Redmond JPOD site facilitating FIH, commercialization and technology development, and evaluation projects. Magnus has over 18 years of industry experience in early to late phase process development, CMC strategy, global tech transfer and technology development in the biopharmaceutical industry. Prior to joining Just, he held roles of increasing responsibility at Dynavax Technologies, Inc., CSL Limited, AGC Biologics and Avid Bioservices, Inc.. Magnus has supported the commercial launch of five biopharmaceuticals, a number of commercial processes and numerous IND/IMPD enabling development programs.
Magnus has received his M.S. in Molecular Biotechnology with a focus on mammalian cell culture from the University Bielefeld, Germany and earned his Ph.D. from the Research Center Juelich and University Bielefeld, Germany with a focus on protein purification development. He also conducted post-graduate research at the University of Minnesota and Rensselaer Polytechnic Institute in biochemical engineering and Deakin University, Melbourne, Australia in corporate management.